According to the new market research “ELISpot and FluoroSpot Assay Market by Product (Assay Kit (T Cell and B Cell assay), Analyzer, Ancillary Products), Application (Transplant, Vaccines, Clinical Trials, Cancer), End User (Hospital, Labs, Research Institute) – Global Forecast to 2023″, analyzes and studies the major market drivers, restraints/challenges, and opportunities. The ELISpot and FluoroSpot market is projected to reach USD 287 million by 2023 from USD 135 million in 2018, at a CAGR of 16.2% during the forecast period.
The global ELISpot and FluoroSpot Assay market is segmented based on product, application, end user and regions.
By product type, the ELISpot and FluoroSpot market is segmented into assay kits, analyzers, and ancillary products. The assay kits are further subsegmented by utility, type, and analyte. In 2018, the assay kits segment is expected to account for the largest share of the market. The rising incidence of chronic diseases and technological advancements are driving the growth of this product segment.
Download a PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=124350584
Browse and in-depth TOC on in “ELISpot and FluoroSpot Assay Market ”
74 – Tables
33 – Figures
111 – Pages
Based on the applications, the ELISpot and FluoroSpot market is segmented into diagnostic and research applications. In 2018, the diagnostic applications segment is expected to account for the larger share of the ELISpot and FluoroSpot market in 2018. The large share of this segment can be attributed to the rising global prevalence of infectious diseases and the increasing use of ELISpot kits for disease diagnosis.
By end user, the ELISpot and FluoroSpot market is segmented into hospitals & clinical laboratories, research institutes, and biopharmaceutical companies. The hospitals & clinical laboratories segment is expected to account for the largest market share in 2018 while the research institutes segment is projected to grow at the highest CAGR during the forecast period. The growing patient population and the improving healthcare infrastructure in developing countries are some of the key factors driving the growth of the hospitals & clinical laboratories segment.
Request Free Sample Report @
North America is expected to command the largest share of the ELISpot and FluoroSpot market. The large share of this regional segment can be attributed to the increasing incidence of chronic diseases. In addition to this, the increasing focus on vaccine development is driving the growth of this market.
The key players in the ELISpot and FluoroSpot Assay market are Oxford Immunotec (UK), Cellular Technologies (US), Mabtech (Sweden), Becton, Dickinson and Company (US), Abcam (UK), Bio-Techne (US), Autoimmun Diagnostika (Germany), Biotech Investissement (France), Lophius Biosciences (Germany), and U-CyTech (Netherlands).
View Complete Press Release @